Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,066 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Overcoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilization.
Niesvizky R, Mark TM, Ward M, Jayabalan DS, Pearse RN, Manco M, Stern J, Christos PJ, Mathews L, Shore TB, Zafar F, Pekle K, Xiang Z, Ely S, Skerret D, Chen-Kiang S, Coleman M, Lane ME. Niesvizky R, et al. Among authors: ward m. Clin Cancer Res. 2013 Mar 15;19(6):1534-46. doi: 10.1158/1078-0432.CCR-12-1429. Epub 2013 Jan 28. Clin Cancer Res. 2013. PMID: 23357980 Free PMC article. Clinical Trial.
Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach.
Ocean AJ, Christos P, Sparano JA, Shah MA, Yantiss RK, Cheng J, Lin J, Papetti M, Matulich D, Schnoll-Sussman F, Besanceney-Webler C, Xiang J, Ward M, Dilts KT, Keresztes R, Holloway S, Chen EX, Wright JJ, Lane ME. Ocean AJ, et al. Among authors: ward m. Invest New Drugs. 2014 Jun;32(3):542-8. doi: 10.1007/s10637-014-0070-0. Epub 2014 Feb 15. Invest New Drugs. 2014. PMID: 24526575 Free PMC article. Clinical Trial.
Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer.
Ocean AJ, Christos P, Sparano JA, Matulich D, Kaubish A, Siegel A, Sung M, Ward MM, Hamel N, Espinoza-Delgado I, Yen Y, Lane ME. Ocean AJ, et al. Among authors: ward mm. Cancer Chemother Pharmacol. 2011 Aug;68(2):379-88. doi: 10.1007/s00280-010-1481-z. Epub 2010 Oct 28. Cancer Chemother Pharmacol. 2011. PMID: 20981545 Free PMC article. Clinical Trial.
Incremental increase in VEGFR1⁺ hematopoietic progenitor cells and VEGFR2⁺ endothelial progenitor cells predicts relapse and lack of tumor response in breast cancer patients.
Jain S, Ward MM, O'Loughlin J, Boeck M, Wiener N, Chuang E, Cigler T, Moore A, Donovan D, Lam C, Cobham MV, Schneider S, Christos P, Baergen RN, Swistel A, Lane ME, Mittal V, Rafii S, Vahdat LT. Jain S, et al. Among authors: ward mm. Breast Cancer Res Treat. 2012 Feb;132(1):235-42. doi: 10.1007/s10549-011-1906-3. Epub 2011 Dec 9. Breast Cancer Res Treat. 2012. PMID: 22160642 Free PMC article. Clinical Trial.
Influencing the Tumor Microenvironment: A Phase II Study of Copper Depletion Using Tetrathiomolybdate in Patients with Breast Cancer at High Risk for Recurrence and in Preclinical Models of Lung Metastases.
Chan N, Willis A, Kornhauser N, Ward MM, Lee SB, Nackos E, Seo BR, Chuang E, Cigler T, Moore A, Donovan D, Vallee Cobham M, Fitzpatrick V, Schneider S, Wiener A, Guillaume-Abraham J, Aljom E, Zelkowitz R, Warren JD, Lane ME, Fischbach C, Mittal V, Vahdat L. Chan N, et al. Among authors: ward mm. Clin Cancer Res. 2017 Feb 1;23(3):666-676. doi: 10.1158/1078-0432.CCR-16-1326. Epub 2016 Oct 21. Clin Cancer Res. 2017. PMID: 27769988 Clinical Trial.
Tetrathiomolybdate-associated copper depletion decreases circulating endothelial progenitor cells in women with breast cancer at high risk of relapse.
Jain S, Cohen J, Ward MM, Kornhauser N, Chuang E, Cigler T, Moore A, Donovan D, Lam C, Cobham MV, Schneider S, Hurtado Rúa SM, Benkert S, Mathijsen Greenwood C, Zelkowitz R, Warren JD, Lane ME, Mittal V, Rafii S, Vahdat LT. Jain S, et al. Among authors: ward mm. Ann Oncol. 2013 Jun;24(6):1491-8. doi: 10.1093/annonc/mds654. Epub 2013 Feb 13. Ann Oncol. 2013. PMID: 23406736 Free PMC article. Clinical Trial.
Ixabepilone-induced mitochondria and sensory axon loss in breast cancer patients.
Ebenezer GJ, Carlson K, Donovan D, Cobham M, Chuang E, Moore A, Cigler T, Ward M, Lane ME, Ramnarain A, Vahdat LT, Polydefkis M. Ebenezer GJ, et al. Among authors: ward m. Ann Clin Transl Neurol. 2014 Sep;1(9):639-49. doi: 10.1002/acn3.90. Epub 2014 Sep 2. Ann Clin Transl Neurol. 2014. PMID: 25493278 Free PMC article.
Correction: Influencing the Tumor Microenvironment: A Phase II Study of Copper Depletion Using Tetrathiomolybdate in Patients with Breast Cancer at High Risk for Recurrence and in Preclinical Models of Lung Metastases.
Chan N, Willis A, Kornhauser N, Ward MM, Lee SB, Nackos E, Seo BR, Chuang E, Cigler T, Moore A, Donovan D, Cobham MV, Fitzpatrick V, Schneider S, Wiener A, Guillaume-Abraham J, Aljom E, Zelkowitz R, Warren JD, Lane ME, Fischbach C, Mittal V, Vahdat L. Chan N, et al. Among authors: ward mm. Clin Cancer Res. 2020 Sep 15;26(18):5051. doi: 10.1158/1078-0432.CCR-20-3177. Clin Cancer Res. 2020. PMID: 32934032 No abstract available.
Tetrathiomolybdate (TM)-associated copper depletion influences collagen remodeling and immune response in the pre-metastatic niche of breast cancer.
Liu YL, Bager CL, Willumsen N, Ramchandani D, Kornhauser N, Ling L, Cobham M, Andreopoulou E, Cigler T, Moore A, LaPolla D, Fitzpatrick V, Ward M, Warren JD, Fischbach C, Mittal V, Vahdat LT. Liu YL, et al. Among authors: ward m. NPJ Breast Cancer. 2021 Aug 23;7(1):108. doi: 10.1038/s41523-021-00313-w. NPJ Breast Cancer. 2021. PMID: 34426581 Free PMC article.
5,066 results